Major study tracks new Drug's fight against aggressive lung cancer
NCT ID NCT07308379
Summary
This study will observe how well the immunotherapy drug toripalimab works in real-world treatment for patients with advanced small cell lung cancer. Researchers will follow about 1200 patients already scheduled to receive this drug as their first treatment, tracking how long the cancer stays controlled and monitoring side effects. The goal is to understand the drug's real-world effectiveness and safety outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.